SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic...

Part 2 of the Phase 2/3 SIGLEC clinical trial is designed and powered to serve as the first pivotal trial to support approval of...

Strasbourg, France & Tokyo, Japan, Jan 9, 2024 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based...

– Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 39% Annual Growth (39%...

Up against an onslaught of lawsuits, 23andMe is denying liability for millions of users' genetic records leaked last fall.In a letter sent to a...

CRISPR ended 2023 with a bang.In November, the gene editing tool scored its first clinical approval for treating sickle cell anemia and beta-thalassemia in...

Google DeepMind Used a Large Language Model to Solve an Unsolvable Math ProblemWill Douglas Heaven | MIT Technology Review“In a paper published in Nature...

<!-- -->The healthcare industry is facing several challenges, including rising costs, increasing complexity, and a growing demand for personalized treatment....

CER-001 treatment attenuated systemic inflammation, downregulated Indoleamine-2,3-dioxygenase (IDO1) thereby reducing neuroactive metabolites and waste accumulation Preclinical data support the concept that the use of CER-001...

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment – –...

OpenAI said Monday that anyone can now create a customized version of ChatGPT without any coding skills. CEO Sam Altman announced the new changes...

In a groundbreaking move, the VitaDAO community has rallied behind the cause of early-stage cancer research by establishing Matrix Biosciences, a cutting-edge biotech company. VitaDAO,...